Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

ANI Pharmaceuticals, Inc. (ANIP) had Revenue of $131.65M for the most recently reported fiscal quarter, ending 2023-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2023-12-31

Income Statement Financials
Revenue	$131.65M
Net Income	$0.75M
Cost of Goods Sold	$53.42M
Gross Profit	$78.23M
Operating Expenses	$124.93M
Operating Income	$6.73M
Non-Operating Income/Expense	$-5.78M
Pre-Tax Income	$0.95M
Normalized Pre-Tax Income	$0.95M
Income after Taxes	$1.16M
Income from Continuous Operations	$1.16M
Consolidated Net Income/Loss	$1.16M
Normalized Income after Taxes	$1.16M
EBIT	$6.73M
EBITDA	$21.92M
Weighted-Average Shares Outstanding (Basic)	18.00M
Weighted-Average Shares Outstanding (Diluted)	18.19M
Earnings per Share (EPS) (Basic)	$0.04
Earnings per Share (EPS) (Diluted)	$0.05
Balance Sheet Financials
Current Assets	$519.82M
Property, Plant, and Equipment	$44.59M
Long-Term Assets	$384.61M
Total Assets	$904.42M
Current Liabilities	$145.48M
Long-Term Debt	$284.82M
Long-Term Liabilities	$301.35M
Total Liabilities	$446.82M
Common Equity	$432.75M
Tangible Shareholders Equity	$220.37M
Shareholders Equity	$457.60M
Common Shares Outstanding	20.48M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$118.96M
Cash Flow from Investing Activities	$-18.51M
Cash Flow from Financial Activities	$67.44M
Beginning Cash	$53.23M
End Cash	$221.12M
Increase/Decrease in Cash	$167.89M
Stock-Based Compensation	$20.65M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	$-1.62M
Fundamental Metrics & Ratios
Current Ratio	3.57
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.38
Debt to Equity Ratio	0.62
Gross Margin	59.42%
Operating Margin	5.11%
EBIT Margin	5.11%
EBITDA Margin	--
Pre-Tax Profit Margin	0.72%
Profit Margin	0.57%
Free Cash Flow	$110.09M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.48
Receiveable Turnover	0.81
Days Sales in Receivables	110.80
Return on Equity	0.27%
Return on Tangible Equity	0.52%
Return on Assets	0.13%
Return on Investments	0.16%
Book Value Per Share	$22.35
Free Cash Flow per Share	$6.05
Operating Cash Flow per Share	$6.54

Data from Zacks Investment Research, Inc.